at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o
Company profile
Ticker
BNGO
Exchange
Website
CEO
R. Erik Holmlin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BioNano Genomics, Inc, Bionano Genomics, Inc, BioNanomatrix Inc
SEC CIK
Corporate docs
Subsidiaries
Bionano Genomics UK, Ltd. • Bionano Genomics (Shanghai) Trading Co., Ltd. • BioDiscovery, Inc • Lineagen, Inc. • Purigen Biosystems, Inc. • PURIGEN BIOSYSTEMS UK LTD ...
BNGO stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
6 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
5 Mar 24
8-K
Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway
28 Feb 24
8-K
Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results
8 Jan 24
8-K
Financial Statements and Exhibits
24 Nov 23
424B3
Prospectus supplement
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress
8 Nov 23
EFFECT
Notice of effectiveness
7 Nov 23
Transcripts
BNGO
Earnings call transcript
2023 Q4
5 Mar 24
BNGO
Earnings call transcript
2023 Q3
8 Nov 23
BNGO
Earnings call transcript
2023 Q2
9 Aug 23
BNGO
Earnings call transcript
2023 Q1
9 May 23
BNGO
Earnings call transcript
2022 Q4
9 Mar 23
BNGO
Earnings call transcript
2022 Q3
4 Nov 22
BNGO
Earnings call transcript
2022 Q2
5 Aug 22
BNGO
Earnings call transcript
2022 Q1
6 May 22
BNGO
Earnings call transcript
2021 Q4
2 Mar 22
BNGO
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 34.97 mm | 34.97 mm | 34.97 mm | 34.97 mm | 34.97 mm | 34.97 mm |
Cash burn (monthly) | (no burn) | (no burn) | 37.74 mm | 18.99 mm | 8.76 mm | 10.83 mm |
Cash used (since last report) | n/a | n/a | 225.82 mm | 113.61 mm | 52.45 mm | 64.79 mm |
Cash remaining | n/a | n/a | -190.85 mm | -78.64 mm | -17.48 mm | -29.82 mm |
Runway (months of cash) | n/a | n/a | -5.1 | -4.1 | -2.0 | -2.8 |
Institutional ownership, Q3 2023
9.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 52 |
Opened positions | 6 |
Closed positions | 74 |
Increased positions | 4 |
Reduced positions | 41 |
13F shares | Current |
---|---|
Total value | 15.77 bn |
Total shares | 5.22 mm |
Total puts | 132.12 k |
Total calls | 153.02 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 1.49 mm | $4.53 bn |
BLK Blackrock | 575.30 k | $1.74 bn |
GMT Capital | 530.26 k | $1.61 bn |
STT State Street | 374.99 k | $1.14 bn |
Mitsubishi UFJ Kokusai Asset Management | 354.05 k | $1.07 bn |
Geode Capital Management | 342.02 k | $1.04 bn |
Dimensional Fund Advisors | 309.35 k | $937.34 mm |
Mirae Asset Global Investments | 204.67 k | $620.14 mm |
Millennium Management | 186.23 k | $564.27 mm |
Susquehanna International | 145.54 k | $441.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | Alka Chaubey | Common Stock | Payment of exercise | Dispose F | No | No | 1.27 | 1,081 | 1.37 k | 31,487 |
15 Feb 24 | Mark Oldakowski | Common Stock | Payment of exercise | Dispose F | No | No | 1.27 | 1,229 | 1.56 k | 48,644 |
15 Feb 24 | Jonathan V. Dixon | Common Stock | Payment of exercise | Dispose F | No | No | 1.27 | 402 | 510.54 | 3,525 |
15 Feb 24 | R. Erik Holmlin | Common Stock | Payment of exercise | Dispose F | No | No | 1.27 | 3,073 | 3.90 k | 77,663 |
18 Sep 23 | Gulsen Kama | Stock Option Common Stock | Grant | Acquire A | No | No | 3 | 106,000 | 318.00 k | 106,000 |
News
Bionano Announces Publication Of A Breast Cancer Study Showing That The Number Of SVs Detected With OGM May Be Related To Prognosis, Tumor Progression And Chemotherapy Resistance
19 Mar 24
Bionano Genomics Sees Q1 Revenue $8.25M-$8.75M Vs $9.69M Est.; FY24 Revenue $37M-$41M Vs $47.17M Est.
5 Mar 24
Earnings Scheduled For March 5, 2024
5 Mar 24
Earnings Outlook For Bionano Genomics
4 Mar 24
How Is The Market Feeling About Bionano Genomics?
26 Jan 24
Press releases
Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
5 Mar 24
Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024
28 Feb 24
Thinking about buying stock in FREYR Battery, BioNano Genomics, New York Community Bancorp, Datasea, or Cheche Group?
14 Feb 24
Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
25 Jan 24
Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
23 Jan 24